DYAI Q1 2026 Earnings EPS Misses Mark as PreRevenue Biotech Maintains Pipeline Focus WB Q3 2025 Earnings EPS of 042 Amidst a Cautious Market Response QS Q1 2026 Earnings Narrower Loss Surprises But Stock Falls 215 Amid Continued PreRevenue Phase Immunovant IMVT Q1 2026 Earnings NarrowerThanExpected Loss but EPS Miss Highlights RD Spending Palantir Q1 2026 Earnings EPS Surpasses Estimates Revenue Details Unavailable Stock Edges Lower OMER Q1 2026 Earnings Narrower Loss Beats Estimates as Pipeline Progress Continues